Pharmacology Flashcards
Atracurium/Cisatricurium Toxicity
produces Laudanosine which causes siezures
Succinylcholine Toxicity
Malignant Hyperthermia (treat with Dantrolene)
Hemodynamic changes
Hyperkalemia (due to upregulation of AchR)
Increase in intraocular/ intracranial pressure
Myoglobinuria
Tubocurarine MOA and action
Non-depolarizing and Moderate Histamine Release
Pancuronium/Rocuronium/Vecuronium MOA and Action
Non-depolarizing, Pancuronium - Moderate block of cardiac M-receptor
Succinylcholine Off target action
Stimulation of Ganglia and Cardiac M-Receptor
Neostigmine/Edrophonium/Pyridostigmine MOA
AchE Inhibitors
Sugammadex MOA
Encapsulates steroids Rocuronium and Verocuronium
Succinylcholine Metabolism
Plasma enzyme Pseudocholinesterase - extremely short mechnism of action
Duloxetine/Milnacipran MOA
SSRI for Fibromyalgia
Duloxetine/Milnacipran Toxicity
Condraindicated in Closed-Angle Glaucoma
BBW: Suicidal Ideation
Hyponatremia - SIADH
CV- increase in HR and BP
Duloxetine/Milnacipran Metabolism
Duloxetine - CYP metabolized and 2D6 inhibitor
Milnacipran - NOT metabolized by CYP
Pregabalin MOA
Fibromyalgia:
Inhibits presynaptic a-2-d subunit of L-Type Ca2+ channels - inhibits the excitatory transmission of Glutamate
Pregabalin Toxicity
Rebound worsening of symptoms on withdrawal
Depression/Suicide
Dizziness, Sedation, blurry vision, xerostomia
Carisoprodol MOA
Muscle Relaxer:
CNS action in Reticular Activating System, sedation and altered perception of pain
Carisoprodol Toxicity
Drowziness, dizziness
CNS effects: agitation, insomnia, vertigo, ataxia
vision loss
Cyclobenzaprine MOA
Muscle Relaxer:
Central action, maybe at level of brainstem
Significant anticholinergic action (leads to side-effects)
Cyclobenzaprine Toxicity
Drowziness, xerostomia, NV, blurred vision
QT prolongation
1st gen Antihistamines - leads to paralytic ileus
Methocarbomol MOA
Muscle Relaxer:
Generalized sedative
CNS effects
Tizanidine MOA
Muscle Relaxer:
Presynaptic alpha-2 receptor agonist, leads to decreased activation of motor neurons (reduces tone but not strength)
Tizanidine Toxicity
Hepatocellular toxicity
CNS effects (additive)
Hypotension (additive)
Baclofen MOA
Spasticity:
GABA-b agonist - produces inhibitory signals/prevents excitatory
Inhibits Substance P action for pain relief
Baclofen Toxicity
BBW: Rebound seizures, confusion, hallucinations, mental health
CNS depression (additive)
Increased blood glucose (diabetics)
Dantrolene MOA
Spasticity:
Interacts with the Ryanodine receptor to interfere with Ca2+ release form SR, uncouples excitation-contraction
Dantrolene Toxicity
Crosses the placenta and causes “Floppy Baby Syndrome”
Vfib and cardiovascular collapse with other Ca-channel blockers
Additive CNS effects
greatest risk for hepatic injury by hypersensitivity mechanism
Sundilac
Reye’s syndrome
Aspirin
Salycilate Poisoning Pathogenesis
Enters CNS to cause hyperventilation by stimulating the medulla.
Uncoupling of ox. Phosphorylation, interupting metabloism
Methotrexate MOA
DMARD:
DHFR Inhibitor
Adenosine inhbition - impairs lymphs and prevents release of cytokines
Methotrexate Toxicity
Increased opportunistic infections and bleeding, avoid vaccinations
Pulmonary Fibrosis
Malignancies, Skin, and GI
Teratogen
Sulfasalazine MOA
DMARD:
Metabolized to Sulfapyridine and Mesalamine - inhibits PG and LT production
Sulfasalazine Toxicity
Fatal blood dyscrasias
Sulfasalazine Contraindication
Contrindicated in history of hypersensitivity to Salicylate or Sulfonamide drugs
Leflunomide MOA
DMARD:
Inhibits Dihydroorate Dehydrogenase
(mitochondrial enzyme for pyrimidine synthesis)
Also uricosuric effect
Leflunomide Toxicity
Do not use in immune suppression or infection
Teratogen
Hydrochloroquine MOA
DMARD:
Increases intracellular vacuole pH, required for MHC Class-II peptide presentation to CD4+ T Cells
Hydrochloroquine Toxicity
Liver toxicity
Blood dyscrasias
CNS toxicity: Seizures, polyneuritis, ototoxicity, neuropathy
Eyes: Corneal opacities, retinopathy, keratopathy
Hydrochloroquine Contraindication
Alcohol use, liver disease
Contraindicated in Ocular disease
Adalimumab MOA
TNF - binds to TNF-a to prevent its interaction